Twitter Logo Youtube Circle Icon LinkedIn Icon

France > Industry focus > Healthcare and life sciences > Law firm and leading lawyer rankings

Editorial

Index of tables

  1. Industry focus: healthcare and life sciences
  2. Other recommended firms
  3. Leading individuals

Leading individuals

  1. 1

Who Represents Who

Find out which law firms are representing which Healthcare and life sciences clients in France using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact david.burgess@legal500.com.

CLICK HERE TO VISIT THE WHO REPRESENTS WHO SITE

Allen & Overy LLP is ‘top of the game’ in the patent space and provides ‘a very high level of service’. The firm has ‘great knowledge of the pharmaceuticals industry (patent and regulatory)’ and handles the most ground-breaking patent litigation cases. Recent cases include litigation regarding the validity of a second medical use patent and successfully defending a client in one of the first cases in France involving antibodies. The firm also handles regulatory and corporate work. Clients include leading pharmaceuticals manufacturers. Global practice co-head Laëtitia Bénard is ‘very impressive and the must-use lawyer in the life sciences area’ for patent litigation. The ‘very thoughtful’ David Por has ‘good analytical and communicative skills’ in patent litigation. Alexandre Rudoni and counsel Eveline Van Keymeulen are other names to note.

The ‘outstandingDechert LLP shows ‘depth of expertise, great responsiveness to clients’ needs and responds by tailor-made services’. The firm has ‘great industry knowledge’ and ‘understands and adapts very well to constraints of a start-up company’. The practice has a wide client base made up of promising biotech firms and large pharmaceuticals groups. It provides a full range of expertise: M&A and private equity, regulatory and competition, patent and product litigation proficiency. The practice recently advised Medtech on a €13.6m issuance of convertible shares and assisted Echosens with a minority investment into the company by Cathay Capital and OrbiMed. Baxter, GlaxoSmithKline and Merck Sharpe & Dohme are also clients. The practice is jointly headed by patent expert Marianne Schaffner and the ‘incredibly smart and responsiveAlain Decombe, who shows ‘great market understanding’. Jacques Sivignon and Mélanie Thill-Tayara, Isabelle Marguet, Anne-Charlotte Rivière are other key names in the group; corporate partner Matthieu Grollemund is also recommended.

Dentons is ‘capable of everything’. The firm provides ‘excellent, precise and strategic work’ and is highly available at all times. The practice, which has deep regulatory and M&A expertise, advises many of the world’s largest pharmaceutical laboratories. It recently assisted Servier Monde with the conclusion of a strategic international partnership with GeNeuro. Pfizer and Takeda are also clients. Pascale Poupelin and Jean-Marc Grosperrin head the team, in which Anne-Laure Marcerou and Olivia Guéguen are other strong assets.

Hogan Lovells (Paris) LLP runs one of the market’s most comprehensive practices. In particular, the team has an impressive product liability caseload, where it is trusted by the largest players in pharmaceuticals, biotech and medical devices; it is involved in the market’s largest ongoing cases, including the high-profile PIP and Gardasil disputes. Practice head Cécile Derycke is a top choice. The firm also has strong regulatory expertise in Mikael Salmela, who recently assisted Bristol-Myers Squibb with setting up its immuno-oncology research foundation. Patent litigation is another top field of expertise, where the team regularly handles cross-border cases for clients such as Eli Lilly. Stanislas Roux-Vaillard is the key contact.

McDermott Will & Emery AARPI has great expertise in collaboration agreements between major laboratories. Recent work includes assisting Servier with its strategic collaboration with Pfizer to develop and commercialise Cellectis’ UCART19 leukaemia treatment, as well as acting for Pierre Fabre in its collaboration with Array Biopharma for two novel oncology products. The team also advises biotech companies during fundraisings and works on e-health projects. Practice head Emmanuelle Trombe and Anthony Paronneau are highly recommended.

Sea Avocats has ‘strong pharmaceutical law and product liability expertise’. The ‘highly available’ team handles sensitive cases and also deals with regulatory matters. It advises leading companies in pharmaceuticals and medical devices, including Pierre Fabre Médicament, Sanofi-Pasteur MSD and Medtronic. The practice co-heads are Alain Gorny, who is ‘a great listener and gives concrete answers’, and Diane Bandon-Tourret.

Simmons & Simmons LLP is the go-to-firm for product liability cases. The team is regularly retained by top laboratories and is currently involved in a high-profile case concerning clinical trials. Alexandre Regniault and global practice head Jacques-Antoine Robert are the key contacts. Other notable contributors are tax expert Jean-Luc Cuadrado, of counsel Eric Nigri – who is a public law expert – and Ombline Ancelin, who recently advised on a merger control matter. MSD is a client.

The ‘excellent’ team at CMS has leading regulatory expertise through the ‘impressiveBernard Geneste, who ‘knows his field and understands rapidly how issues may be solved’. The team regularly challenges government rulings on drug price reimbursement, while Jean de la Hosseraye handles product liability work. Arnaud Hugot recently advised on several clinic-related transactions such as Medipole Partenaires’ sale of three sites in Paris.

De Gaulle Fleurance & Associés has top regulatory expertise and also is increasingly being retained to advise on e-health projects; IP is another strong area. The firm represents some major laboratories as well as some start-ups and biotech companies. Jean-Marie Job and Cécile Théard-Jallu are the key contacts.

Fieldfisher provides ‘excellent analysis’ for its growing client base, which includes leading pharmaceuticals and other medical manufacturers. The six-lawyer team is consulted on regulatory issues or in the context of French authority (ANSM) controls, as well as handling litigation. The key contacts are Brigitte Daille-Duclos and practice head Olivier Lantrès, who is ‘committed to the commercial success of his clients’ projects’.

Gide Loyrette Nouel A.A.R.P.I. is involved in high-profile domestic and cross-border patent proceedings in the pharmaceuticals industry, including representing Ono Pharmaceuticals and Bristol-Myers Squibb in the French aspects of a patent dispute relating to a revolutionary immuno-oncology treatment. Grégoire Triet, Arnaud Michel, Emmanuel Larere and Raphaëlle Dequiré-Portier are all recommended. The firm also advises a number of biotech companies in financing, corporate transactions and IPOs.

HBC Avocats has ‘a strong reputation in the biotechnology sector’. The ‘always available’ team has great expertise in licensing and R&D for innovator companies. It assisted Valneva with the negotiation of a major R&D agreement with GlaxoSmithKline. Jonathan Burnham has ‘great knowledge of the industry and provides high-quality intellectual property and contract legal support’.

Intuity often assists leading laboratories and medical devices companies with regulatory, litigious and competition issues; product liability is another strong area of expertise. Christophe Hénin and Anne Servoir are highly recommended.

Reed Smith advises several leading US pharmaceuticals and medical devices manufacturers on regulatory and patent issues. IP experts Marina Cousté and François Jonquères have ‘great business acumen’. The IP practice is notably representing Novozymes in a sue-and-countersue patent dispute with DSM. Daniel Kadar is a key contact for regulatory work. The practice also handles litigation through Benoît Charot and Marie Albertini. The firm also advises various biotech companies on their corporate transactions, such as assisting bioMérieux with the acquisition of Applied Maths. Marc Fredj and Isabelle MacElhone are the key contacts.

Viguié Schmidt’s Etienne Gouesse assists leading laboratories in sensitive product liability cases and also handles regulatory and public sector procurement work.

Winston & Strawn LLP is top-end in a specialised niche of representing clinics and alternative healthcare provides, where it provides ‘one-of-a-kind, in-depth knowledge and extensive experience of the healthcare sector’. The ‘high-quality and friendly’ lawyers ‘meet their clients’ demands and anticipate what will need to be done’. The firm advises health institutions, clinics, professional organisations and practitioners. The practice is quite unique in its combination of strong regulatory, M&A and litigation expertise. Mutuelle Nationale des Hospitaliers, Ramsay Générale de Santé and Point Vision are clients. Practice head Gilles Bigot is ‘outstanding: his knowledge of the sector is unmatched and he has excellent judgement’. Also recommended are Jérôme Herbet and of counsel Florence Naudin, who are ‘responsive and experts in their fields’. Anne-Carine Ropars-Furet and Guillaume-Denis Faure are other names to note.

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

GC Powerlist -
Europe

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in France

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • The new French regulation applying to national insurance contributions for managers and shareholders

    French insurance contributions on executive and shareholder remuneration (pay + dividends) have been substantially increased by the National Insurance Funding for 2013 Act, No. 2012-1404, of 17th December 2012. Until 31st December 2012, all dividends were subject to national insurance contributions on unearned income but henceforth, under Article L136-3 of the National Insurance Code, amended by Act No. 2012-1404, certain dividends   are considered as pay received by executives and shareholders and are therefore subject to the national insurance contributions on pay. The Act also abolished the ceiling on health insurance contributions payable by the self-employed and all this means that businesses must rethink the way that they have been structured until now.
  • CHINA - PERSONAL TAXATION AND SOCIAL SECURITY : CHINESE AND FOREIGN NATIONALS ON AN EQUAL FOOTING

    The People's Republic of China has initiated an overhaul of its social security system, reformed the personal taxation regime and has extended the scope of these laws to foreigners residing in China.
  • MOROCCO TO BECOME THE LEADING FINANCIAL PLACE IN AFRICA

    The Kingdom of Morocco is supporting the ambition of becoming the leading financial place for Africa. In this context, a wave of draft laws is to be passed and implemented within the following months, amongst which, the Law No. 53.08, setting up a new financial authority, and the Law No. 54.08, reforming public offering rules, are of paramount importance to Moroccan and foreign issuers, and financial institutions.
  • ACQUISITIONS IN CHINA : ASSET OR SHARE DEAL?

    The opportunities offered to foreign investors by the Chinese mergers and acquisitions market are increasing every year: in 2010, transactions involving foreign companies came to 60.1 billion euros, an increase of 21.2% compared with 2009. Seen from the West, where markets are declining, all sectors of the Chinese economy seem to be undergoing promising development and the statistics indicate that the Middle Empire will be a lasting springboard for growth.
  • Prime de Partage des Profits

    Le dispositif L’article 1er de la loi de financement rectificative de la Sécurité sociale pour 2011 oblige les sociétés commerciales de 50 salariés et plus, dont les dividendes par part sociale ou par action sont en augmentation par rapport à la moyenne des deux années précédentes, à verser une prime à l’ensemble de leurs salariés
  • BULGARIA MARKET OVERVIEW

    Types of investors The private equity (PE) funds that are active in Bulgaria are not raised or registered in the country. Some Bulgarian PE funds were raised recently, but there are no statistics as to the sources of their funding, their number, the funds that were accumulated, etc.
  • RECENT DEVELOPMENTS REGARDING COMMITMENTS

    THE PROCEDURE IS CLARIFIED, BUT MAY COMMITMENTS APPLY WITHOUT LIMIT?
  • Landmark decision by French Competition Authority in conditioned LPG case

    cartel case closed after discovery that leniency application was largely based on forgeries and rejection of collective dominant position objection.
  • 2012 supplementary budget

    The second supplementary budget published in the Official Gazette September 19, 2011 provides for two key measures that affect the deferral of tax losses and taxation of capital gains realized on the sale of equity securities .
  • Actualité législative fiscale

    Au delà des mesures applicables à l’ensemble des contribuables (telles que la limitation du report des déficits ou la réforme du mode de calcul des plus values sur cessions de participations),le plan de réduction des déficits annoncé le 24 août dernier par le gouvernement comprend des mesures qui intéressent spécifiquement les acteurs du secteur financier.

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to